Antraglycosides in oncology: efficacy and mechanisms of side effects

Read full text Summarise with VIRAT
Authors: Є. О. Чуфицький, L. V. Derymedvid
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Oncological diseases occupy the second place in the structure of mortality of the population of Ukraine. Despite the emergence of targeted drugs, anthracycline group antitumor antibiotics (doxorubicin, daunorubicin, epirubicin, etc.) remain basic cytostatics included in the WHO list of essential medicines. At the same time, improving long-term survival of cancer patients has actualized the problem of severe long-term complications of chemotherapy, which requires a detailed study of the safety profile of these drugs and their availability on the domestic market. The article systematizes modern data on the mechanisms of action of anthraglycoside antitumor antibiotics, mechanisms of their side effects and specific toxicity profile. The pathogenesis of key dose-limiting complications is characterized: hematotoxicity (the most frequent acute reaction - 35-42%), cardiotoxicity (registered in 57% of cases and carries the highest risk of mortality), gonadotoxicity with a high risk of irreversible infertility, as well as anthracycline-associated tumorigenesis (secondary leukemias with a short latency period of 1–3 years).

Fields of Study & Subjects

Chemotherapy-induced cardiotoxicity and mitigation Cancer therapeutics and mechanisms Bioactive Compounds and Antitumor Agents

Publication details

Journal / source
Likarska sprava
Issue
1
Publication date
31 March 2026
Language
EN